246 related articles for article (PubMed ID: 33215343)
61. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Chemotherapy in the Management of Adults With Newly Diagnosed Metastatic Brain Tumors.
Sherman JH; Lo SS; Harrod T; Hdeib A; Li Y; Ryken T; Olson JJ
Neurosurgery; 2019 Mar; 84(3):E175-E177. PubMed ID: 30629221
[TBL] [Abstract][Full Text] [Related]
62. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Lieberman FS; Wang M; Robins HI; Tsien CI; Curran WJ; Werner-Wasik M; Smith RP; Schultz C; Hartford AC; Zhang P; Mehta MP
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):878-886. PubMed ID: 30496882
[TBL] [Abstract][Full Text] [Related]
63. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
64. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
Mao Y; Yao Y; Zhang LW; Lu YC; Chen ZP; Zhang JM; Qi ST; You C; Wang RZ; Yang SY; Zhang X; Wang JS; Chen JX; Yang QY; Shen H; Li ZY; Wang X; Ma WB; Yang XJ; Zhen HN; Zhou LF
Chin Med J (Engl); 2015 Oct; 128(20):2751-8. PubMed ID: 26481741
[TBL] [Abstract][Full Text] [Related]
65. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
66. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
67. What next for newly diagnosed glioblastoma?
Domingo-Musibay E; Galanis E
Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493
[TBL] [Abstract][Full Text] [Related]
68. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Whole Brain Radiation Therapy in Adults With Newly Diagnosed Metastatic Brain Tumors.
Gaspar LE; Prabhu RS; Hdeib A; McCracken DJ; Lasker GF; McDermott MW; Kalkanis SN; Olson JJ
Neurosurgery; 2019 Mar; 84(3):E159-E162. PubMed ID: 30629211
[TBL] [Abstract][Full Text] [Related]
69. Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma.
Gupta T; Selvarajan JMP; Kannan S; Menon N; Dasgupta A; Chatterjee A
Neurooncol Adv; 2023; 5(1):vdad086. PubMed ID: 37638346
[TBL] [Abstract][Full Text] [Related]
70. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M
J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423
[TBL] [Abstract][Full Text] [Related]
71. Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma.
Lahmi L; Idbaih A; Rivin Del Campo E; Hoang-Xuan K; Mokhtari K; Sanson M; Canova CH; Carpentier A; Jacob J; Maingon P; Feuvret L
J Clin Neurosci; 2019 Oct; 68():39-44. PubMed ID: 31399318
[TBL] [Abstract][Full Text] [Related]
72. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
[TBL] [Abstract][Full Text] [Related]
73. Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Adilijiang A; Hirano M; Okuno Y; Aoki K; Ohka F; Maeda S; Tanahashi K; Motomura K; Shimizu H; Yamaguchi J; Wakabayashi T; Natsume A
Molecules; 2019 Aug; 24(17):. PubMed ID: 31443404
[TBL] [Abstract][Full Text] [Related]
74. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
75. A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma.
Attarian F; Taghizadeh-Hesary F; Fanipakdel A; Javadinia SA; Porouhan P; PeyroShabany B; Fazilat-Panah D
Front Oncol; 2021; 11():779491. PubMed ID: 34900732
[TBL] [Abstract][Full Text] [Related]
76. Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.
Mallick S; Gandhi AK; Rath GK
Indian J Med Paediatr Oncol; 2015; 36(4):229-37. PubMed ID: 26811592
[TBL] [Abstract][Full Text] [Related]
77. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults.
Patrick HH; Sherman JH; Elder JB; Olson JJ
J Neurooncol; 2022 Jun; 158(2):167-177. PubMed ID: 35246769
[TBL] [Abstract][Full Text] [Related]
78. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults.
Ziu M; Goyal S; Olson JJ
J Neurooncol; 2022 Jun; 158(2):255-264. PubMed ID: 34748120
[TBL] [Abstract][Full Text] [Related]
79. Impact of standard care on elderly glioblastoma patients.
Lapointe S; Florescu M; Simonyan D; Michaud K
Neurooncol Pract; 2017 Mar; 4(1):4-14. PubMed ID: 31385982
[TBL] [Abstract][Full Text] [Related]
80. Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.
Gozdz A
Curr Oncol; 2023 Nov; 30(11):9676-9688. PubMed ID: 37999122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
